Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
——
Summit Therapeutics logo
Summit TherapeuticsSMMT
——
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Bicara Therapeutics's convertible preferred stock outstanding shares?
Bicara Therapeutics (BCAX) reported convertible preferred stock outstanding shares of 0 in Q1 2026.